EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Risk factors for relapse in ANCA ‐associated vasculitis among patients with relapse after induction of remission with rituximab

Ellen Romich iD, Joshua F Baker iD, Thomas R Riley iD, Ian Green iD, Rennie L Rhee iD, Carol A McAlear iD, Ulrich Specks iD, Rona M Smith iD, David R Jayne iD, Peter A Merkel iD, RITAZAREM Investigators

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.70025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Ellen Romich und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia. Hauptthemen laut MEDLINE: Rituximab, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antirheumatic Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIH HHS, Versus Arthritis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy.

Methods

This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase (MPO)‐ANCA who achieved remission after re‐induction with rituximab and glucocorticoids were randomized at month 4 to receive continued rituximab or azathioprine for a maintenance period up to 24 months, followed by observation until relapse or up to 48 months. Generalized estimating equations logistic regression identified baseline and time‐varying risk factors for relapse by the next visit for the two study phases: maintenance (months 4‐24) and off‐treatment (months 24‐48).

Results

Among 170 patients (median (IQR) age 59 (48‐68) years, disease duration 5 (2‐10) years), 99 relapses occurred (46 during maintenance). During maintenance, musculoskeletal involvement (odds ratio (OR) [95% confidence interval (CI)]: 2.8 [1.1, 7.2], p=0.03) and higher patient global assessment (OR [95% CI]: 1.1 [1.0, 1.2], p=0.04) were associated with relapse. During the off‐treatment phase, presence of CD19+ B‐cells (OR [95% CI]: 2.5 [1.2, 5.1], p=0.01) and reappearance of ANCA (OR [95% CI]: 3.2 [1.3, 7.7], p=0.01) were each associated with higher relapse risk. Multivariable analysis identified markers of inflammation (changes in platelets, white blood cells, and immunoglobulin A) associated with relapse.

Conclusions

Risk factors for relapse in AAV vary by treatment phase. Monitoring markers of inflammation and immune reconstitution may identify patients at risk for relapse, particularly after treatment withdrawal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntirheumatic AgentsHumansFemaleMiddle AgedMaleRecurrenceRisk FactorsAgedRemission InductionAzathioprineGlucocorticoidsAntibodies, Antineutrophil CytoplasmicImmunosuppressive Agents

Substanzen

RituximabAzathioprineGlucocorticoidsAntirheumatic AgentsAntibodies, Antineutrophil CytoplasmicImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia.
  • Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia.
  • Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
  • Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

ORCID-Profile: Ellen Romich, Joshua F Baker, Thomas R Riley, Ian Green, Rennie L Rhee, Carol A McAlear, Ulrich Specks, Rona M Smith, David R Jayne, Peter A Merkel

Förderung

  • NIAMS NIH HHS
  • NIH HHS
  • Versus Arthritis
  • NCRR NIH HHS
  • Roche
  • NIGMS NIH HHS
  • Rehabilitation Research and Development Service
  • RRD VA

Zitieren

APA

Romich, E., Baker, J. F., Riley, T. R., Green, I., Rhee, R. L., McAlear, C. A., Specks, U., Smith, R. M., Jayne, D. R., Merkel, P. A., & RITAZAREM Investigators (2025). Risk factors for relapse in ANCA ‐associated vasculitis among patients with relapse after induction of remission with rituximab. Arthritis & Rheumatology. https://doi.org/10.1002/art.70025

Vancouver

Romich E, Baker JF, Riley TR, Green I, Rhee RL, McAlear CA, et al. Risk factors for relapse in ANCA ‐associated vasculitis among patients with relapse after induction of remission with rituximab. Arthritis & Rheumatology. 2025. doi:10.1002/art.70025

BibTeX
@article{Romich2025,
  author = {Romich, Ellen and Baker, Joshua F and Riley, Thomas R and Green, Ian and Rhee, Rennie L and McAlear, Carol A and Specks, Ulrich and Smith, Rona M and Jayne, David R and Merkel, Peter A and RITAZAREM Investigators, RITAZAREM Investigators},
  title = {Risk factors for relapse in ANCA ‐associated vasculitis among patients with relapse after induction of remission with rituximab},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.70025}
}
Kostenlos starten →